Profile data is unavailable for this security.
About the company
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
- Revenue in GBP (TTM)0.00
- Net income in GBP-1.63m
- Incorporated2021
- Employees5.00
- LocationGenflow Biosciences PLC6 Heddon StreetLONDON W1B 4BTUnited KingdomGBR
- Websitehttps://genflowbio.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
ValiRx Plc | 9.60k | -2.04m |
TheraCryf PLC | 396.00k | -3.14m |
Fusion Antibodies PLC | 1.14m | -2.23m |
IXICO PLC | 6.00m | -1.87m |
ImmuPharma PLC | -69.96k | -2.46m |
Genflow Biosciences PLC | 0.00 | -1.63m |
Synairgen plc | 0.00 | -6.92m |
Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
LungLife AI Inc | 21.69k | -3.34m |
Oxford Biodynamics PLC | 617.00k | -11.11m |
OptiBiotix Health PLC | 644.00k | -2.04m |
Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Premier Fund Managers Ltd.as of 09 Apr 2024 | 32.00m | 9.15% |